Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 94, Issue 3, 2016, Pages 605-611

  Lewis, Stephen L ^a   Patel, Pretesh ^a   Song, Haijun ^a   Freedland, Stephen J ^b   Bynum, Sigrun ^a   Oh, Daniel ^a   Palta, Manisha ^a   Yoo, David ^a   Oleson, James ^a   Salama, Joseph K ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENS; DISEASES; PATIENT TREATMENT; RADIATION; RADIOTHERAPY; UROLOGY;

ANDROGEN DEPRIVATION THERAPY; BIOCHEMICAL RELAPSE-FREE SURVIVAL; COMMON TERMINOLOGY CRITERIA; GENITOURINARY TOXICITIES; INTENSITY MODULATED RADIATION THERAPY; METHODS AND MATERIALS; PROSTATE SPECIFIC ANTIGEN; RADIATION THERAPY ONCOLOGY GROUPS;

TOXICITY;

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOCHEMICAL RECURRENCE; CANCER RADIOTHERAPY; CANCER SURGERY; FOLLOW UP; GLEASON SCORE; HEMATURIA; HEMORRHOID; HUMAN; HYPOFRACTIONATED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION INJURY; SEXUAL DYSFUNCTION; URINE INCONTINENCE; ADVERSE EFFECTS; BLOOD; IMAGE GUIDED RADIOTHERAPY; MIDDLE AGED; POSTOPERATIVE CARE; PROCEDURES; PROSTATIC NEOPLASMS; TIME FACTOR;

ADULT; AGED; DOSE HYPOFRACTIONATION; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE CARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, IMAGE-GUIDED; RADIOTHERAPY, INTENSITY-MODULATED; TIME FACTORS;

EID: 84963774134     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2015.11.025     Document Type: Article

References (34)

1. National Cancer Institute Cancer statistics, vol. 2014 2014 National Cancer Institute Bethesda, Maryland
2. A.V. D'Amico, M.H. Chen, A.A. Renshaw, and et al. Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial JAMA 299 2008 289 295
3. P.A. Kupelian, L. Potters, D. Khuntia, and et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer Int J Radiat Oncol Biol Phys 58 2004 25 33
4. M. Bolla, H. van Poppel, B. Tombal, and et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: Long-term results of a randomised controlled trial (EORTC trial 22911) Lancet 380 2012 2018 2027
5. A.J. Stephenson, P.T. Scardino, M.W. Kattan, and et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy J Clin Oncol 25 2007 2035 2041
6. I.M. Thompson Jr., C.M. Tangen, J. Paradelo, and et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial JAMA 296 2006 2329 2335
7. B.J. Trock, M. Han, S.J. Freedland, and et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy JAMA 299 2008 2760 2769
8. T. Wiegel, D. Bottke, U. Steiner, and et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pt3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95 J Clin Oncol 27 2009 2924 2930
9. I.M. Thompson, C.M. Tangen, J. Paradelo, and et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-term followup of a randomized clinical trial J Urol 181 2009 956 962
10. T. Wiegel, D. Bartkowiak, D. Bottke, and et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial Eur Urol 66 2014 243 250
11. G.P. Swanson, M.A. Hussey, C.M. Tangen, and et al. Predominant treatment failure in postprostatectomy patients is local: Analysis of patterns of treatment failure in SWOG 8794 J Clin Oncol 25 2007 2225 2229
12. A.J. Stephenson, P.T. Scardino, J.A. Eastham, and et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy J Clin Oncol 23 2005 7005 7012
13. D.J. Brenner, A.A. Martinez, G.K. Edmundson, and et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue Int J Radiat Oncol Biol Phys 52 2002 6 13
14. W.D. D'Souza, and H.D. Thames Is the alpha/beta ratio for prostate cancer low? Int J Radiat Oncol Biol Phys 51 2001 1 3
15. J.F. Fowler, M.A. Ritter, R.J. Chappell, and et al. What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys 56 2003 1093 1104
16. C.R. King, and J.F. Fowler A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low Int J Radiat Oncol Biol Phys 51 2001 213 214
17. S. Arcangeli, L. Strigari, S. Gomellini, and et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer Int J Radiat Oncol Biol Phys 84 2012 1172 1178
18. K.E. Hoffman, K.R. Voong, T.J. Pugh, and et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: Results from a randomized trial Int J Radiat Oncol Biol Phys 88 2014 1074 1084
19. P.A. Kupelian, T.R. Willoughby, C.A. Reddy, and et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 gy per fraction) for localized prostate cancer: Cleveland Clinic experience Int J Radiat Oncol Biol Phys 68 2007 1424 1430
20. A. Pollack, G. Walker, E.M. Horwitz, and et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer J Clin Oncol 31 2013 3860 3868
21. D. Dearnaley, I. Syndikus, G. Sumo, and et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: Preliminary safety results from the CHHIP randomised controlled trial Lancet Oncol 13 2012 43 54
22. W.R. Lee, J.J. Dignam, M. Amin, and et al. NRG oncology RTOG 0415: A randomized phase III non-inferiority study comparing 2 fractionation schedules in patients with low risk prostate cancer Int J Radiat Oncol Biol Phys 94 2015 3 4
23. T.J. Kruser, D.F. Jarrard, A.K. Graf, and et al. Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence Cancer 117 2011 2629 2636
24. M. Massaccesi, S. Cilla, F. Deodato, and et al. Hypofractionated intensity-modulated radiotherapy with simultaneous integrated boost after radical prostatectomy: Preliminary results of a phase II trial Anticancer Res 33 2013 2785 2789
25. J.M. Michalski, C. Lawton, I. El Naqa, and et al. Development of rtog consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer Int J Radiat Oncol Biol Phys 76 2010 361 368
26. A. Dasu Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials? Clin Oncol 19 2007 289 301
27. W. Shipley, D. Hunt, H.R. Lukka, and et al. Initial report of rtog 9601, a phase iii trial in prostate cancer: Effect of anti-androgen therapy (aat) with bicalutamide during and after radiation therapy (RT) on freedom from progression and incidence of metastatic disease in patients following radical prostatectomy (RP) with pt2-3, n0 disease and elevated PSA levels J Clin Oncol 29 2011 1
28. A. Goenka, J.M. Magsanoc, X. Pei, and et al. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy Eur Urol 60 2011 1142 1148
29. D.M. Moreira, L.L. Bañez, J.C. Presti Jr., and et al. Predictors of secondary treatment following biochemical recurrence after radical prostatectomy: Results from the shared equal access regional cancer hospital database BJU Int 105 2010 28 33
30. M.A. Sidhom, A.B. Kneebone, M. Lehman, and et al. Post-prostatectomy radiation therapy: Consensus guidelines of the Australian and New Zealand Radiation Oncology Genitourinary Group Radiother Oncol 88 2008 10 19
31. M. Bolla, H. van Poppel, L. Collette, and et al. Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911) Lancet 366 2005 572 578
32. C. Cozzarini, C. Fiorino, C. Deantoni, and et al. Higher-than-expected severe (grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: A single-institution analysis of 1176 patients Eur Urol 66 2014 1024 1030
33. P. Poortmans, A. Bossi, K. Vandeputte, and et al. Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group Radiother Oncol 84 2007 121 127
34. K.L. Wiltshire, K.K. Brock, M.A. Haider, and et al. Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomy Int J Radiat Oncol Biol Phys 69 2007 1090 1099